They identified lymphoid enhancer-binding factor 1 (LEF1) as a major downstream target of ΔNp63 that plays a crucial role in cancer development, and the activity of ΔNp63 was pleiotropic in various kinds of cancer, suggesting LEF1 could be another useful target for the treatment of certain cancers, including SCC. This evidence concerns the gene LEF1 and cancer.